(BMEA) Biomea Fusion - Overview
Stock: Diabetes, Obesity, Oral, Covalent, Menin Inhibitor
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 101% |
| Relative Tail Risk | -8.26% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.49 |
| Alpha | -91.51 |
| Character TTM | |
|---|---|
| Beta | 1.450 |
| Beta Downside | 0.821 |
| Drawdowns 3y | |
|---|---|
| Max DD | 97.71% |
| CAGR/Max DD | -0.52 |
Description: BMEA Biomea Fusion January 19, 2026
Biomea Fusion, Inc. (NASDAQ:BMEA) is a clinical-stage biotechnology firm founded in 2017 and based in San Carlos, California. The company’s strategy is to develop oral covalent small-molecule therapeutics for metabolic diseases, with its lead candidate icovamenib-a potent, orally bioavailable covalent inhibitor of the menin scaffold protein that modulates epigenetic gene regulation and influences cell-cycle control, apoptosis, and DNA-damage repair.
Key operational metrics (as of the most recent 10-Q) show a cash runway of roughly $45 million, supporting the planned Phase 1b/2a trial of icovamenib slated for Q3 2026. The global obesity-treatment market is projected to exceed $50 billion by 2030, and menin-targeted agents have attracted $1.2 billion in total venture funding across the sector, indicating strong capital appetite for this mechanism of action. Additionally, the U.S. FDA’s recent guidance on accelerated pathways for metabolic indications could shorten time-to-market if early efficacy signals are robust.
For a deeper, data-driven look at BMEA’s valuation dynamics, you might find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -95.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -1.58 > 0.02 and ΔFCF/TA -55.55 > 1.0 |
| NWC/Revenue: 2777 % < 20% (prev 1075 %; Δ 1702 % < -1%) |
| CFO/TA -1.58 > 3% & CFO -87.1m > Net Income -95.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (40.6m) vs 12m ago 12.17% < -2% |
| Gross Margin: 59.02% > 18% (prev 0.62%; Δ 5840 % > 0.5%) |
| Asset Turnover: 1.47% > 50% (prev 5.56%; Δ -4.09% > 0%) |
| Interest Coverage Ratio: -79.32 > 6 (EBITDA TTM -95.1m / Interest Expense TTM -1.22m) |
Altman Z'' -15.00
| A: 0.61 (Total Current Assets 49.4m - Total Current Liabilities 15.6m) / Total Assets 55.2m |
| B: -8.22 (Retained Earnings -453.7m / Total Assets 55.2m) |
| C: -1.17 (EBIT TTM -96.9m / Avg Total Assets 82.8m) |
| D: -11.47 (Book Value of Equity -453.7m / Total Liabilities 39.6m) |
| Altman-Z'' Score: -42.68 = D |
What is the price of BMEA shares?
Over the past week, the price has changed by +8.93%, over one month by -3.17%, over three months by -6.15% and over the past year by -70.39%.
Is BMEA a buy, sell or hold?
- StrongBuy: 4
- Buy: 3
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BMEA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7 | 473.8% |
| Analysts Target Price | 7 | 473.8% |
| ValueRay Target Price | 0.8 | -33.6% |
BMEA Fundamental Data Overview February 05, 2026
Revenue TTM = 1.22m USD
EBIT TTM = -96.9m USD
EBITDA TTM = -95.1m USD
Long Term Debt = 6.88m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 787.0k USD (from shortTermDebt, last quarter)
Debt = 6.88m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -39.8m USD (from netDebt column, last quarter)
Enterprise Value = 38.7m USD (78.5m + Debt 6.88m - CCE 46.6m)
Interest Coverage Ratio = -79.32 (Ebit TTM -96.9m / Interest Expense TTM -1.22m)
EV/FCF = -0.44x (Enterprise Value 38.7m / FCF TTM -87.1m)
FCF Yield = -225.1% (FCF TTM -87.1m / Enterprise Value 38.7m)
FCF Margin = -7143 % (FCF TTM -87.1m / Revenue TTM 1.22m)
Net Margin = -7845 % (Net Income TTM -95.7m / Revenue TTM 1.22m)
Gross Margin = 59.02% ((Revenue TTM 1.22m - Cost of Revenue TTM 500.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.70 (Enterprise Value 38.7m / Total Assets 55.2m)
Interest Expense / Debt = 14.25% (Interest Expense 980.0k / Debt 6.88m)
Taxrate = 21.0% (US default 21%)
NOPAT = -76.6m (EBIT -96.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.18 (Total Current Assets 49.4m / Total Current Liabilities 15.6m)
Debt / Equity = 0.44 (Debt 6.88m / totalStockholderEquity, last quarter 15.6m)
Debt / EBITDA = 0.42 (negative EBITDA) (Net Debt -39.8m / EBITDA -95.1m)
Debt / FCF = 0.46 (negative FCF - burning cash) (Net Debt -39.8m / FCF TTM -87.1m)
Total Stockholder Equity = 30.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -115.6% (out of range, set to none)
RoE = -310.1% (Net Income TTM -95.7m / Total Stockholder Equity 30.9m)
RoCE = -256.9% (out of range, set to none) (EBIT -96.9m / Capital Employed (Equity 30.9m + L.T.Debt 6.88m))
RoIC = -248.1% (out of range, set to none) (NOPAT -76.6m / Invested Capital 30.9m)
WACC = 11.26% (E(78.5m)/V(85.4m) * Re(11.26%) + D(6.88m)/V(85.4m) * Rd(14.25%) * (1-Tc(0.21)))
Discount Rate = 11.26% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.60%
Fair Price DCF = unknown (Cash Flow -87.1m)
EPS Correlation: 1.41 | EPS CAGR: 8.62% | SUE: 0.23 | # QB: 0
Revenue Correlation: 12.43 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.17 | Chg30d=-0.005 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=-1.05 | Chg30d=-0.023 | Revisions Net=-1 | Growth EPS=+29.6% | Growth Revenue=+0.0%